Top in rheumatology: Protecting patients from COVID-19, fatigue in rheumatic diseases
Click Here to Manage Email Alerts
In a new editorial, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, talks about issues that rheumatologists face in the era of COVID-19.
According to Calabrese, one of the greatest concerns among rheumatologists is how to protect immunosuppressed patients from severe COVID-19. His editorial was the top story in rheumatology last week.
In another top story, rheumatologists discuss the intense fatigue that patients with rheumatic or autoimmune diseases face on a daily basis. Physical and mental wellness can help mitigate this symptom, experts said.
Read these and more top stories in rheumatology below:
COVID-19 in the eighth inning: Outpatient care of immunosuppressed patients
Last July, I wrote an editorial entitled “The rheumatologist, the third inning of COVID-19 and the importance of masks.” Thinking back and wondering where we are now, I would say the top of the eighth! Read more.
Battling the ‘bone-crushing weariness’ of fatigue in rheumatic diseases
There is tired, and there is fatigue. Then there is fatigue associated with a rheumatic or autoimmune disease, which is multifactorial and debilitating and has confounded physicians and patients for decades. Read more.
Daily glucocorticoids exceeding 5 mg 'threshold' linked to higher cardiovascular risk in RA
Daily glucocorticoid doses of 5 mg or more during the preceding 6 or 12 months is associated with an increased risk for cardiovascular events in steroid-naïve patients with rheumatoid arthritis, according to data. Read more.
Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors
Despite a low number of major adverse cardiovascular events overall, patients with psoriatic arthritis who newly start IL-12/23 or IL-17 inhibitors have a greater cardiovascular risk than those who begin TNF inhibitors, according to data. Read more.
Guselkumab 100 mg improves fatigue in psoriatic arthritis through 1 year
Guselkumab 100 mg administered every 4 or 8 weeks produced “meaningful and sustained” improvements in fatigue through 1 year in patients with psoriatic arthritis, according to data published in Arthritis & Research & Therapy. Read more.